PropertyValue
?:abstract
  • Opioid treatment programs (OTPs) that dispense methadone got a fast and clear reprieve from federal authorities last week in the face of COVID-19 The Drug Enforcement Administration (DEA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) issued policies that give OTPs flexibility in take-homes, limiting the frequency of face-to-face contact and opportunities for transmission of COVID-19 There is also greater flexibility for office-based opioid treatment (OBOT) with buprenorphine
?:creator
?:journal
  • Alcoholism_&_Drug_Abuse_Weekly
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • DEA, SAMHSA relax OTP/OBOT regulations due to COVID-19
?:type
?:who_covidence_id
  • ##BR#\'11383
  • #11383
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/faxr2kag>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/faxr2kag>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all